Filtros de búsqueda

Lista de obras de

Changes in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century

scientific article published on 16 May 2019

Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century

article

In Reply

Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: a large international population-based study

artículo científico publicado en 2018

Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century

artículo científico publicado en 2013

Recent improvement in survival of patients with multiple myeloma: variation by ethnicity

artículo científico publicado en 2013

Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups

artículo científico publicado en 2012

Survival disparities by insurance type for patients aged 15-64 years with non-Hodgkin lymphoma

artículo científico publicado en 2015

Survival of adults with acute lymphoblastic leukemia in Germany and the United States

artículo científico publicado en 2014

Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications

artículo científico publicado en 2018

Survival of patients with gastric lymphoma in Germany and in the United States

artículo científico publicado en 2015

Survival of patients with hepatobiliary tract and duodenal cancer sites in Germany and the United States in the early 21st century

artículo científico publicado en 2018

Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century ⬇️

artículo científico publicado el 3 de diciembre de 2012

Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century

artículo científico publicado en 2015

U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission

scientific article published on 24 April 2019

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda